EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo

Qihong Yang, Kenneth Kin Wah To, Guilin Hu, Kai Fu, Chuan Yang, Shuangli Zhu, Can Pan, Fang Wang, Kewang Luo, Liwu Fu

Cell Communication and Signaling · 13.06.2024 · 22 (1)

DOI: 10.1186/s12964-024-01698-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Communication and Signaling, online erschienen am 13.06.2024. Verfasst von Qihong Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: People's Hospital of Longhua, Shenzhen, 518109, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Drug Resistance, Multiple. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research & Development Program of China, Foundation of Guangdong Esophageal Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multidrug resistance (MDR) limits successful cancer chemotherapy. P-glycoprotein (P-gp), BCRP and MRP1 are the key triggers of MDR. Unfortunately, no MDR modulator was approved by FDA to date. Here, we will investigate the effect of BI-2865, a pan-KRAS inhibitor, on reversing MDR induced by P-gp, BCRP and MRP1 in vitro and in vivo, and its reversal mechanisms will be explored.

Methods

The cytotoxicity of BI-2865 and its MDR removal effect in vitro were tested by MTT assays, and the corresponding reversal function in vivo was assessed through the P-gp mediated KBv200 xenografts in mice. BI-2865 induced alterations of drug discharge and reservation in cells were estimated by experiments of Flow cytometry with fluorescent doxorubicin, and the chemo-drug accumulation in xenografts’ tumor were analyzed through LC-MS. Mechanisms of BI-2865 inhibiting P-gp substrate’s efflux were analyzed through the vanadate-sensitive ATPase assay, [ 125 I]-IAAP-photolabeling assay and computer molecular docking. The effects of BI-2865 on P-gp expression and KRAS-downstream signaling were detected via Western blotting, Flow cytometry and/or qRT-PCR. Subcellular localization of P-gp was visualized by Immunofluorescence.

Results

We found BI-2865 notably fortified response of P-gp-driven MDR cancer cells to the administration of chemo-drugs including paclitaxel, vincristine and doxorubicin, while such an effect was not observed in their parental sensitive cells and BCRP or MRP1-driven MDR cells. Importantly, the mice vivo combination study has verified that BI-2865 effectively improved the anti-tumor action of paclitaxel without toxic injury. In mechanism, BI-2865 prompted doxorubicin accumulating in carcinoma cells by directly blocking the efflux function of P-gp, which more specifically, was achieved by BI-2865 competitively binding to the drug-binding sites of P-gp. What’s more, at the effective MDR reversal concentrations, BI-2865 neither varied the expression and location of P-gp nor reduced its downstream AKT or ERK1/2 signaling activity.

Conclusions

This study uncovered a new application of BI-2865 as a MDR modulator, which might be used to effectively, safely and specifically improve chemotherapeutic efficacy in the clinical P-gp mediated MDR refractory cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmDrug Resistance, MultipleHumansAnimalsMiceCell Line, TumorATP Binding Cassette Transporter, Subfamily B, Member 1Xenograft Model Antitumor AssaysMice, NudeDoxorubicinMice, Inbred BALB CFemale

Stichwörter der Autor:innen

ABC transportersABCB1/P-gpBI-2865Chemotherapeutic agentCombination therapyKRAS inhibitorMultidrug resistance

Substanzen

ATP Binding Cassette Transporter, Subfamily B, Member 1Doxorubicin

Autor:innen und Institutionen

  • People's Hospital of Longhua, Shenzhen, 518109, China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
  • School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, 999077, China.
  • State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, China.
  • People's Hospital of Longhua, Shenzhen, 518109, China. kewangluo@126.com.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China. fulw@mail.sysu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • National Key Research & Development Program of China
  • Foundation of Guangdong Esophageal Cancer Institute

Zitieren

APA

Yang, Q., To, K. K. W., Hu, G., Fu, K., Yang, C., Zhu, S., Pan, C., Wang, F., Luo, K., & Fu, L. (2024). BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo. Cell Communication and Signaling, 22(1). https://doi.org/10.1186/s12964-024-01698-4

Vancouver

Yang Q, To KKW, Hu G, Fu K, Yang C, Zhu S, et al. BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo. Cell Communication and Signaling. 2024;22(1). doi:10.1186/s12964-024-01698-4

BibTeX
@article{Yang2024,
  author = {Yang, Qihong and To, Kenneth Kin Wah and Hu, Guilin and Fu, Kai and Yang, Chuan and Zhu, Shuangli and Pan, Can and Wang, Fang and Luo, Kewang and Fu, Liwu},
  title = {BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo},
  journal = {Cell Communication and Signaling},
  year = {2024},
  volume = {22},
  number = {1},
  doi = {10.1186/s12964-024-01698-4}
}
Kostenlos starten →